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Abstract
Background: Tribbles 3 (TRB3) affects insulin signalling by inhibiting insulin-stimulated Akt phosphorylation and
subsequent activation. A single nucleotide polymorphism located in the second extron of the human TRB3 gene is
thought to be associated with insulin resistance. The latter is a core abnormality in PCOS independent of obesity.
The present study was designed to clarify the relationships of TRB3 Q84R polymorphism with PCOS in a Chinese
women group.
Methods: A case-control study with two groups: PCOS group (n = 336) and control group of infertility women for
tubal and/or male factor (n = 116) was performed. Genotyping of the TRB3 R84 variant was determined by
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: The frequency of genotype QQ in PCOS women was significantly lower, while genotype QR and RR were
significantly higher than that in control group (p < 0.05). However, the difference disappeared after adjustment for
BMI. At glucose1h, glucose2h and insulin2h point, the difference between QQ individuals and R84 allele carriers in
PCOS women reached statistical significance during OGTT (p < 0.05).
Conclusions: TRB3 Q84R polymorphism is associated with obesity and especially glucose metabolism and not
associated with polycystic ovary syndrome because of compositional characteristics of phenotype in Chinese PCOS
women.
Background
Polycystic ovary syndrome (PCOS) is a common endo-
crine disorder with amenorrhoea (or oligomenorrhoea),
hyperandrogenism, hirsutism, obesity and insulin resis-
tance (IR). It affects 5-10% reproductive aged women
and is a leading cause of female infertility [1]. It is a
complex and heterogeneous disorder due to the interac-
tion of multiple genetic defects and environmental fac-
tors [2]. Candidate genes for etiology of PCOS involve
in ovarian and adrenal steroidogenesis, steroid hormone
actions, gonadotropin action and regulation, insulin
action and secretion, energy homeostasis, chronic
inflammation and others [3]. Insulin resistance is a
pathophysiological contributor in around 50% to 80% of
women with PCOS [4]. It is well established that hyper-
insulinemia and insulin resistance are common bio-
chemical features of PCOS independent of obesity [5].
Insulin resistance is associated with hyperandrogenemia
and anovulation in PCOS women [6,7]. As is well
known, hyperandrogenism and anovulation are impor-
tant clinical features and diagnostic criteria for polycys-
tic ovary syndrome [8]. Besides, PCOS women are at
substantial risks for development of glucose intolerance,
diabetes, lipid abnormalities and cardiovascular abnorm-
alities since they often have insulin resistance [6].
Tribbles 3 (TRB3), a mammalian homolog of Droso-
phila tribbles also known as TRIB3/NIPK (gene ID
57761), affects insulin signalling by inhibiting insulin-sti-
mulated Akt phosphorylation. Literature has shown that
mice with overexpressing TRB3 had increased liver glu-
cose output and become hyperglycemic [9]. The expres-
sion of TRB3 mRNA and protein increased in skeletal
muscle and liver from female rat offspring which were
insulin-resistant diabetes [10,11]. In human, hepatic
mRNA expression of TRB3 was significantly increased
in obese people with insulin resistance [12]. TRB3 pro-
tein level in skeletal muscle significantly elevated in type
2 diabetes mellitus (T2DM) patients [13]. Studies had
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ciated with insulin resistance and related cardiovascular
risk [14-18]. In terms of mechanism for the above phe-
nomenon, mice overexpressing TRB3 R84 in beta cells
displayed decreased beta cell mass [19]. All the above
results suggested that TRB3 was associated with insulin
resistance. Yet this hypothesis has not been tested in
PCOS patients.
The current study aims at examining the relationships
of TRB3 Q84R polymorphism with insulin resistance in
a group of Chinese women patients with PCOS.
Methods
Subjects
The PCOS patients in this study were consisted of 336
infertile women aged 17-40. The diagnosis of PCOS was
based on the Rotterdam criteria [8]. Two out of three of
the following criteria were required for the diagnosis:
oligo-ovulation and/or anovulation, clinical and/or bio-
chemical signs of hyperandrogenism and polycystic
ovaries (by transvaginal ultrasound). Patients with the
following disorders were excluded: hyperprolactinemia,
nonclassic congenital adrenal hyperplasia, Cushing’s syn-
drome, androgen-secreting neoplasms and thyroid dys-
function. Oligo-ovulation and/or anovulation were
defined by the presence of oligomenorrhea or amenor-
rhea respectively. Hyperandrogenism was defined as the
clinical presence of hirsutism (Ferriman-Gallwey score
≥6), acne, or alopecia and/or elevated androgen levels
according to normal reference values (total serum tes-
tosterone >2.8 nmo/l). Polycystic ovarian morphology
was examined by trans-vaginal ultrasound and polycystic
ovary was defined by presence of 12 or more follicles in
each ovary measuring 2-9 mm in diameter, and/or
increased ovarian volume (>10 ml) during the follicular
phase of a menstrual cycle. A diagnosis of PCOS was
made only after prolactin, FSH, E2,T S H ,a n d1 7 - h y d r o -
xyprogesterone (17-HP) levels had been measured to
exclude hyperprolactinemia, premature ovarian failure,
hypothalamic amenorrhea, thyroid disorders, and 21-
hydroxylase-deficient nonclassic adrenal hyperplasia
(NCAH), respectively. Cushing’s syndrome and andro-
gen-secreting neoplasms were excluded by clinical pre-
sence, history and laboratory examinations.
The control group included 116 age-matched women
with regular menstrual cycles who were infertile for
tubal and/or male factor. They have no polycystic
ovaries and no clinical or biochemical signs of
hyperandrogenism.
None of the patients had taken any medications affect-
ing glucose metabolism during the preceding 3 months.
The study was approved by the institutional ethics com-
mittee, and written informed consent was obtained from
each patient.
Hormonal and biochemical measures
Fasting blood samples were taken during the follicular
phase of a menstrual cycle (spontaneous or bleeding
after progestin withdrawal) of all women. Luteinizing
hormone (LH), follicle stimulating hormone (FSH) and
total serum testosterone concentrations (T) were deter-
mined by chemiluminescence immunoassay. Total cho-
lesterol (CHO) and triglycerides (TG) were determined
by oxidase method, HDL-cholesterol (HDL) by synthetic
polymer/detergent HDL-C assay (SPD method) and
LDL-cholesterol (LDL) by surfactant LDL-C assay (SUR
method).
A 75 g oral glucose tolerance test was performed in
each PCOS woman. Blood was obtained for glucose and
insulin determinations at 0 h, 1 h and 2 h after glucose
load. Glucose levels were detected using the glucose oxi-
dase method and insulin levels were determined by che-
miluminescence immunoassay. Insulin resistance (IR)
was assessed by the homeostasis model assessment
(HOMA), which was calculated as [fasting insulin con-
centration (μIu/ml) × fasting glucose concentration
(mmol/l]/22.5 [20]. Body mass index (BMI) was calcu-
lated as body weight (kg) divided by body height
squared (m
2).
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using the standard salting-out method [21]. The
purity and concentration of the isolated DNA was mea-
sured. Genotyping of the TRB3 R84 variant was per-
formed by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) as pre-
viously described [14]. Five percent of samples from
both PCOS and control women were re-genotyped by
other laboratory personnel and no discrepancy in geno-
typing was noticed.
Statistical analysis
The Kolmogorov-Smirnov test was used to test for nor-
mal distribution. Comparisons of continuous variables
between groups were conducted by unpaired student’st
test. Mann-Whitney U-test was used when continuous
variables did not meet the normal distribution. The Chi-
square test was used to analyze the associations between
categorical variables. All analyses were performed by
SPSS software version 17.0 (SPSS Inc. Chicago, IL,
USA). Tests of statistical significance were two-sided
and taken as significant when P < 0.05.
Results
The basal demographical, hormonal and biochemical
parameters of control and PCOS women are summar-
ized in Table 1. As expected, significantly higher levels
of BMI, T, LH/FSH ratio, fasting glucose, CHO, TG and
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group while the levels of HDL were significantly lower
in PCOS women (p < 0.05).
Comparison of TRB3 Q84R polymorphism between PCOS
and control women
Genotyping for the TRB3 Q84R polymorphism was shown
in Figure 1. The genotype frequencies were in agreement
with the Hardy-Weinberg equilibrium (P > 0.05 for all ana-
lyses). Genotype frequency was significantly different
between PCOS and control women (Table 2). The fre-
quencies of R allele were 19.5% in PCOS women and
12.5% in control, and Q allele were 80.5% and 87.5%
respectively (P = 0.016). However, the significant difference
disappeared after adjustment for BMI by dividing patients
into four subgroups according to BMI (Asia-Pacific criteria:
underweight: <18.5 kg/m
2; normal weight: 18.5-22.9 kg/m
2;
overweight: 23.0-24.9 kg/m
2;o b e s e :≥25.0 kg/m
2).
Comparison of TRB3 Q84R polymorphism between PCOS
women with IR and without IR
PCOS group was divided into insulin resistance group
(PR group) and non-insulin resistance group (PNR
group) according to HOMA-IR, with a threshold value
of 2.69 [22]. In PCOS women, the frequencies of QR
and RR genotypes in non-insulin resistance group were
lower than insulin resistance group while QQ genotype
was higher, but with no statistical significance ( see
Table 3).
TRB3 Q84R polymorphism and main clinical features of
PCOS women
In further analysis, PCOS women were divided into
hyperandrogenism group and non-hyperandrogenism
group according to serum total testosterone concentra-
tion. TRB3 Q84R genotype distribution is shown in
Table 4. The frequencies of QR and RR genotypes in
non-hyperandrogenism group were lower while QQ
genotype was higher than hyperandrogenism group,
though not significant. Similar tendency of genotype dis-
tribution was observed between oligo/anovulation group
and ovulation group in PCOS women, which are shown
in Table 5.
TRB3 Q84R polymorphism and glucose metabolism of
PCOS women
Because of the small number of RR individuals, subjects
with QR and RR genotypes were considered together as
R84 carriers. The endocrine and metabolic characteris-
tics of PCOS women by TRB3 Q84R genotype are
shown in Table 6. At each time point of OGTT, the
median values of glucose levels were higher in R84 car-
riers than QQ individuals. The similar trend was also
Table 1 Clinical and endocrine-metabolic parameters in
control and PCOS women
control (n = 116) PCOS (n = 336)
Age(yr) 30 (21-41) 29 (18-40)
BMI(kg/m
2) 22 (16-29) 24 (16-35)*
LH/FSH 0.5 (0.2-2.1) 1.3 (0.1-6.4)*
T(nmol/l) 0.7 (0.02-1.9) 1.7 (0.02-7)*
Glu0(mmol/l) 4.8 (3.7-6.0) 5.0 (3.5-8.7)*
CHO(mmol/l) 4.3 (2.7-7.2) 4.9 (3.0-7.8)*
TG(mmol/l) 0.9 (0.3-3.2) 1.3 (0.4-5.9)*
HDL(mmol/l) 1.3 (0.8-2.2) 1.2 (0.7-2.3)*
LDL(mmol/l) 2.4 (1.0-5.0) 2.8 (0.6-6.2)*
Mann-Whitney U-test; Data are described in median (range); BMI:body mass
index; LH:luteinizing hormone; FSH: follicle stimulating hormone; T:total serum
testosterone;Glu0:fasting glucose; CHO:total cholesterol; TG:triglycerides; HDL:
HDL-cholesterol; LDL: LDL-cholesterol. *: p < 0.05.
Figure 1 The representative electrophoretic gel featuring the
RFLP analysis of TRB3 Q84R polymorphism. The PCR products
were digested with MspІ followed by 2% agarose gel
electrophoresis: the resulting wild-type (QQ) samples contained one
band sized 593 bp, heterozygotes (QR) samples contained two
bands sized 593 bp and 297 bp and homozygotes (RR) contained
one band sized 297 bp. M: 100 bp DNA marker; 1: RR genotype;
2,3,5,9,11,12: QQ genotype; 4,6,7,8,10: QR genotype.
Table 2 TRB3 Q84R genotype distribution in PCOS and
control women
genotype PCOS control P
n = 336 n = 116
QQ 209 (62.2%) 88 (75.9%) 0.02
QR 123 (36.6%) 27 (23.3%)
RR 4 (1.2%) 1 (0.9%)
alleles
Q 541 (80.5%) 203 (87.5%) 0.016
R 131 (19.5%) 29 (12.5%)
Chi-square test; Data are presented as number and (percentage).
Table 3 TRB3 Q84R genotype distribution in PCOS
women with IR and without IR
genotype PR PNR P
n = 143 n = 193
QQ 81 (56.6%) 128 (66.3%) 0.104
QR 59 (41.3%) 64 (33.2%)
RR 3 (2.1%) 1 (0.5%)
Chi-square test; Data are presented as number and (percentage). IR: insulin
resistance. PR: PCOS with insulin resistance; PNR: PCOS without insulin
resistance.
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se1h, glucose2h and insulin2h point, the difference
between genotype QQ individuals and R84 carriers
reached statistical significance. Regarding to TRB3
Q84R polymorphism in PCOS women, there was a step-
wise increase in BMI and HOMA-IR from Q84Q to
Q84R and R84R genotype, although not significant.
Discussion
T h es p e c t r u mo fe v i d e n c ef o rP C O Sg e n e t i cb a s i si s
very board. Molecular defects in gonadotrophins and
their receptors, in enzymes involved in steroidogenesis,
as well as those contributed to insulin resistance and
its sequelae, have been the principal focus of family-
based linkage analysis and case-control studies. The
common occurrence of insulin resistance and pancrea-
tic b-cell dysfunction in association with PCOS and
the increased risk for development of T2DM is now
well recognized [23,24]. Moreover, insulin acting
through its receptor stimulates steroidogenesis. This
has led investigations to focus on insulin resistance in
PCOS [6]. Gene variants related to insulin resistance
such as insulin gene (VNTR), insulin receptor (INSR),
insulin receptor substrate proteins (IRS1/2) and cal-
pain-10 have shown to be associated with PCOS and
related metabolic abnormality [25-28]. Particular inter-
est is the implications of TRB3 as a candidate gene for
insulin resistance [29]. Given the fact that insulin resis-
tance is one of the prominent features in PCOS, it is
reasonable to investigate TRB3 polymorphism in
P C O S .T ot h eb e s to fo u rk n o w l e d g e ,t h i si st h ef i r s t
such attempt to analyze TRB3 Q84R polymorphism in
polycystic ovary syndrome.
In terms of the possible mechanism of TRB3 implica-
tion in insulin resistence and hence in PCOS, studies
has found that TRB3 is located on 20p13-p12 of human
chromosomal region that has been confirmed to be
associated with human type 2 diabetes [30]. It is
reported that TRB3 impairs insulin signalling through
the inhibition of Akt phosphorylation and plays a role in
insulin resistance [9]. It has also been demonstrated that
the prevalent TRB3 missense Q84R polymorphism is
significantly associated with several insulin resistance-
related abnormalities in two independent cohorts of
nondiabetic individuals. In fact, serum insulin levels
were significantly different across the three genotype
groups and higher in R84R individuals independent of
BMI [14]. In addition, one study of 716 T2DM patients
showed that the insulin resistance-related cardiovascular
risk significantly increased in R84R individuals. In view
of these findings, TRB3 Q84R polymorphism might also
play a role as an insulin-resistance related factor in the
pathogenesis of PCOS.
In our research, genotype frequency of Q84R was sig-
nificantly different between PCOS and control women.
The frequency of the R allele was significantly higher in
PCOS women, while Q allele was significantly lower.
Study has been demonstrated that R84 carriers had an
increased risk of early-onset T2DM [17]. When either
Q84 or R84 TRB3 full-length cDNAs were transfected
in human HepG2 hepatoma cell lines, as compared with
control HepG2 cells, insulin-induced Ser473-Akt phos-
phorylation was reduced by 22% in Q84- and, of note,
by 45% in R84-transfected cells [14]. Study in human
umbilical vein endothelial cell (HUVEC) naturally carry-
ing different TRB3 genotypes (QQ,QR or RR) showed
that cells carrying the TRB3 R84 variant (i.e., either QR-
Table 4 TRB3 Q84R genotype distribution in PCOS
women divided into hyperandrogenism group and non-
hyperandrogenism group
genotype HA NHA P
n = 65 n = 271
QQ 34 (52.3%) 175 (64.6%) 0.12
QR 30 (46.2%) 93 (34.3%)
RR 1 (1.5%) 3 (1.1%)
Chi-square test; Data are presented as number and (percentage). HA:
hyperandrogenism; NHA: non-hyperandrogenism
Table 5 TRB3 Q84R genotype distribution in PCOS
women divided into oligo/anovulation group and
ovulation group
genotype oligo/anovulation ovulation P
n = 307 n = 29
QQ 189 (61.6%) 20 (69%) 0.687
QR 114 (37.1%) 9 (31%)
RR 4 (1.3%) 0 (0%)
Chi-square test; Data are presented as number and (percentage). oligo/
anovulation: cycle intervals > 35 days or absence of menstruation for 3
consecutive months; ovulation: cycle intervals ≤ 35 days
Table 6 Clinical and endocrine-metabolic characteristics
of PCOS women according to TRB3 Q84R genotype
QQ (n = 209) QR+ RR (n = 127)
Age(yr) 28 (17-40) 28 (19-38)
BMI(kg/m
2) 24 (16-33) 25 (17-35)
LH/FSH 1.27 (0.01-5.2) 1.48 (0.22-6.4)
T(nmol/l) 1.6 (0.21-7.11) 1.7 (0.02-6.14)
HOMA-IR 2.2 (0.4-12.3) 2.6 (0.4-12.8)
glu0h(mmol/l) 4.8 (3.5-8.7) 4.9 (3.7-8.0)
glu1h(mmol/l) 7.4 (3.3-17.9) 8.2 (3.4-60.1)*
glu2h(mmol/l) 6.2 (3.5-16.8) 6.6 (3.4-50.8)*
Ins0h(μIU/ml) 9.7 (2.0-56.6) 11.8 (2.0-45.8)
Ins1h(μIU/ml) 74.6 (1.2-300) 86.8 (7.1-300)
Ins2h(μIU/ml) 67.3 (6.8-300) 76.5 (6.7-300)*
Mann-Whitney U-test; Data are described in median (range); HOMA-IR:
homeostatic model assessment of insulin resistance;glu:glucose; Ins:insulin. *:
p < 0.05.
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reduced insulin-induced nitric oxide (NO) production as
compared to the QQ-cells [15]. In our study, the analy-
sis was adjusted for BMI as those studies reported that
TRB3 was associated with obesity [12]. The significant
difference of genotype frequency between PCOS and
control women failed to be detected after adjustment
for BMI. Different genotype frequency in control and
PCOS group due to different BMI, and lost significance
after BMI adjustment partly confirm association of
Q84R with obesity, although the genotype groups of
PCOS patients did not differ significantly in BMI. In
further analysis, there was no significant difference in
the genotype frequency between PCOS women with IR
and without IR. Furthermore, we could not find an asso-
ciation between the R84 variant and anovulation or ele-
vated total testosterone levels, which are main clinical
characteristics of PCOS associated with insulin resis-
tance in PCOS women. In addition, our study shows
that R84 carriers of PCOS women have higher LH/FSH
ratios. This is in line with the well known fact that
women with polycystic ovary syndrome appear to have
an increased luteinizing hormone pulse frequency [31].
It is possible that TRB3 R84 variant may be implicated
in abnormal secretion of LH by certain underlying
mechanism in PCOS women. However, the difference
was not significant. Taken together, our results suggest
that TRB3 Q84R polymorphism is associated with obe-
sity while not with PCOS and insulin resistance of
PCOS in Chinese women.
Meanwhile, subjects with R84 variant had higher glu-
cose1h, glucose2h, insulin2h levels than individuals with
QQ genotype in PCOS women (p < 0.05), which sug-
gested that R84 variant increased the risk of glucose
metabolic abnormality in PCOS women. This is consis-
tent with observation from 645 non-diabetic subjects
that the mean glucose levels were significantly higher in
R84 carriers than QQ individuals and the mean insulin
levels were higher in R84 carriers than QQ individuals
with no significance at each time point of OGTT [17].
Indeed, R84 carriers were found to be insulin resistant
compared with QQ individuals when studied by euglyce-
mic, hyperinsulinemic clamp, a method that does not
rely on endogenous insulin production for measuring
insulin sensitivity [14]. Besides, the Q84R variant was
associated with higher fasting insulin and higher
HOMA-IR in T2DM group in Chinese population [16].
In the present study, there was a trend towards higher
BMI and HOMA-IR in R84 allele carriers in comparison
with QQ individuals in PCOS women, although with no
statistical significance (Table 6). The observation was in
accordance with the study about metabolic syndrome
[18]. It is not surprising considering that both the poly-
cystic ovary syndrome and the metabolic syndrome
share insulin resistance as a central pathogenetic feature
[32]. Thus, combined with other results on non-PCOS
individuals, it may be deduced that the R84 variant is
associated with glucose metabolic abnormality and is
not associated with PCOS.
The above results of our study should be put into the
context of the fact that the spectrum of clinical features
of PCOS is very diverse and heterogeneous. The pheno-
type varies widely depending on life stage, genotype,
ethnicity and environmental factors. Until recently no
universally accepted clinical definition existed for PCOS.
In past, only the classic phenotype of chronic anovula-
tion and hyperandrogenism was included in the PCOS
diagnosis [33]. The Rotterdam criteria are more exten-
sive, including patients with distinct clinical appearances
besides classic phenotype of PCOS. In fact, according to
these guidelines, PCOS includes four different pheno-
types: [1] O+H+P (oligo- and/or anovulation+hyperan-
drogenism+ polycystic ovaries); [2] O+H; [3] H+P; [4] O
+P. It has been reported that different phenotypes of
PCOS are distinct in clinical and endocrine characteris-
tics, especially for nonhyperandrogenic PCOS phenotype
that may develop PCOS by a different pathogenetic
pathway [34-36]. Oligoanovulatory patients with PCO
but without hyperandrogenism have mild endocrine and
m e t a b o l i cf e a t u r e so fP C O S .T h ep r e v a l e n c eo fm e t a -
bolic syndrome and insulin resistance was lower in this
phenotype with normal androgens compared with other
phenotypes [35,36]. Similar to above reports, the preva-
lence of insulin resistance was lowest in nonhyperandro-
genic PCOS phenotype (data not shown) in our study.
In addition, relative prevalence of each phenotype differs
for different racial and ethnic populations and different
regions [34-36]. The relative prevalence of four pheno-
type in the present study was 16.6% (56/336), 5.1% (17/
336), 8.0% (27/336) and 70.2% (236/336). The pattern of
relative prevalence of four phenotypes of PCOS in pre-
sent study, e.g., the prevalence of nonhyperandrogenic
PCOS phenotype (O+P) was the highest and classic phe-
notype (O+H) was the lowest, was consistent with the
results from a large-scale Chinese population [35]. Thus
it is suspected that diverse compositional characteristics
of phenotype in Chinese PCOS women may account for
this observation that TRB3 Q84R is not associated with
PCOS in the current study and this certainly merit
further investigations with better categorizations of
PCOS population.
Conclusions
Taking together, the current study shows that TRB3
Q84R polymorphism is associated with obesity and
especially glucose metabolism while is not associated
with polycystic ovary syndrome and insulin resistance of
PCOS in Chinese women. Further studies with a greater
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ing to different phenotypes of PCOS are necessary to
confirm these findings.
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